Recent Articles

• 
  MedTech

  In Severe Trauma, REBOA Is Key to Buying Time

  Jang Sung-wook, professor of Cardiovascular and Thoracic Surgery at Dankook University Hospital (head of the Chungnam Regional Trauma Center, second from left), provides training on Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA), a procedure that can be used to respond to massive

  2025.12.24
• 
  Medical / Clinical Case

  Disease That Hardens Lungs Shifts From Transplants to New Drugs

  Idiopathic pulmonary fibrosis is a chronic progressive disease in which fibrosis of lung tissue progresses without a clear cause and the lungs gradually harden. It is a rare, intractable disease that occurs in about 10 people per 100,000 population. Dry cough, shortness of breath, and fatigue are th

  2025.12.24
• 
  Medical

  87% of Doctors Say Obesity Drugs Help Patients

  The Korean Society for the Study of Obesity pointed out in its “Survey on the Current Status of Obesity Treatment and Management” that there is a social atmosphere that fails to recognize obesity as a disease and structural limitations that make it difficult to provide appropriate obesity treatment.

  2025.12.24
• 
  MedTech

  Viewtel Wins Approval for Noninvasive Glucose Monitor, Speeds IPO Next Year

  Non-invasive blood glucose meter ‘Happy Zone’. Courtesy of Beautel South Korea is estimated to have about 6 million diabetes patients and 15 million people in the pre-diabetic stage, but only 600,000 are properly managing their blood glucose levels. This is largely due to the inconvenience and pain

  2025.12.24
• 
  GC Genome

  Global Precision Medicine Push Speeds Post-IPO Growth

  ‘G-SeNTInEL’, the core technology behind ai-CANCERCH, is an analysis platform based on whole genome sequencing (WGS). Provided by GC Genome GC Genome (CEO Ki Chang-seok), which holds the largest clinical genomic testing portfolio in Korea, is accelerating its expansion into global markets this year,

  2025.12.24
• 
  Medical / Research

  Daewoong Pharmaceutical Hosts 4D Symposium on Personalized Diabetes Care

  Panoramic view of Daewoong Pharmaceutical’s 4D Symposium Daewoong Pharmaceutical announced on the 23rd that it discussed initial treatment strategies and criteria for drug selection in relation to this year’s revised diabetes treatment guidelines through its academic program “4D Symposium (Diabetes

  2025.12.23
• 
  Global Expansion

  Samsung Biologics Secures US Base, Easing Tariff Risk

  Samsung Biologics has secured its first production base in the United States by signing an agreement to acquire a U.S. biopharmaceutical manufacturing facility. With expectations rising that the company will benefit from the recent passage of the U.S. “Biosecurity Act” targeting China, the move is s

  2025.12.23
• 
  Biopharma

  Pharma-Bio Group Urges Full Review of Drug Pricing Reform

  Exterior view of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. Provided by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association The Korea Pharmaceutical and Bio-Pharma Manufacturers Association held an emergency press conference on the 22nd at the association’s offi

  2025.12.23
• 
  R&D

  Kolmar Korea Taps Native Plants for Future Cosmetics

  Kolmar Korea announced on the 22nd that it has partnered with the National Institute of Biological Resources to discover next-generation microbiome cosmetic ingredients by utilizing microbial resources inhabiting Korea’s native plants (indigenous to Korea). With this collaboration, Kolmar Korea plan

  2025.12.22
• 
  Global Expansion

  Samsung Biologics Buys US Plant for KRW 413.6b

  Panoramic view of Samsung Biologics headquarters (courtesy of Samsung Biologics) Samsung Biologics has moved to acquire a production plant in the United States and completely eliminate tariff-related uncertainties. On the 22nd, Samsung Biologics announced that it had signed an agreement with global

  2025.12.22